Chevy Chase Trust Holdings LLC reduced its holdings in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 1.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 213,586 shares of the medical device company’s stock after selling 2,244 shares during the period. Chevy Chase Trust Holdings LLC owned about 0.05% of DexCom worth $29,624,000 at the end of the most recent quarter.
Several other large investors have also recently added to or reduced their stakes in DXCM. DSM Capital Partners LLC purchased a new stake in DexCom during the 4th quarter worth approximately $28,000. Valley National Advisers Inc. increased its stake in DexCom by 73.0% during the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after buying an additional 103 shares during the period. Riverview Trust Co acquired a new position in DexCom during the 1st quarter worth approximately $32,000. MV Capital Management Inc. grew its holdings in DexCom by 99.3% during the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after acquiring an additional 138 shares in the last quarter. Finally, Smithfield Trust Co grew its holdings in DexCom by 103.1% during the 4th quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock worth $40,000 after acquiring an additional 165 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.
DexCom Price Performance
NASDAQ:DXCM traded up $0.15 during mid-day trading on Wednesday, hitting $110.99. 993,108 shares of the company’s stock traded hands, compared to its average volume of 2,886,575. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90. The firm’s 50 day simple moving average is $120.40 and its 200 day simple moving average is $125.22. DexCom, Inc. has a 1 year low of $74.75 and a 1 year high of $142.00. The company has a market cap of $44.14 billion, a PE ratio of 71.51, a price-to-earnings-growth ratio of 2.71 and a beta of 1.16.
Insider Buying and Selling at DexCom
In other news, EVP Matthew Vincent Dolan sold 1,990 shares of the business’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $137.81, for a total transaction of $274,241.90. Following the transaction, the executive vice president now directly owns 42,377 shares of the company’s stock, valued at $5,839,974.37. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other DexCom news, EVP Michael Jon Brown sold 652 shares of the business’s stock in a transaction on Friday, May 31st. The shares were sold at an average price of $119.24, for a total transaction of $77,744.48. Following the completion of the sale, the executive vice president now owns 67,560 shares in the company, valued at $8,055,854.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Matthew Vincent Dolan sold 1,990 shares of the business’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $137.81, for a total transaction of $274,241.90. Following the sale, the executive vice president now owns 42,377 shares of the company’s stock, valued at approximately $5,839,974.37. The disclosure for this sale can be found here. Insiders have sold a total of 6,102 shares of company stock valued at $755,103 over the last ninety days. Corporate insiders own 0.30% of the company’s stock.
Analysts Set New Price Targets
Several research analysts have recently issued reports on the stock. Canaccord Genuity Group upped their target price on shares of DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a report on Friday, April 26th. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a report on Monday, June 10th. Raymond James upped their price target on shares of DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a research report on Friday, April 26th. UBS Group upped their price target on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Finally, Royal Bank of Canada assumed coverage on shares of DexCom in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price target for the company. Four equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $140.33.
Check Out Our Latest Stock Analysis on DexCom
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
Recommended Stories
- Five stocks we like better than DexCom
- What are earnings reports?
- This Stock’s Price Shifts Into High Gear With Analyst Upgrades
- What Are Dividend Contenders? Investing in Dividend Contenders
- AI Boosts Glass Tech Leader Stock: Shares Up 75% and More to Come
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- AI Partnership Boosts This Top Tech Stock: Ready for More Gains?
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM – Free Report).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.